Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Increase in Short Interest

Key Points

• Pharming Group N.V. experienced a significant increase in short interest, rising by 372.7% from 1,100 shares to 5,200 shares as of July 31st.
• The company reported $0.06 EPS, surpassing analyst expectations of ($0.10), with quarterly revenue reaching $93.20 million.
• An institutional investor, EverSource Wealth Advisors LLC, purchased 2,979 shares of Pharming Group during the second quarter, valued at approximately $32,000.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) was the recipient of a significant growth in short interest in the month of July. As of July 31st, there was short interest totaling 5,200 shares, agrowthof372.7% from the July 15th total of 1,100 shares. Approximately0.0% of the shares of the company are short sold. Based on an average trading volume of 5,500 shares, the days-to-cover ratio is presently 0.9 days. Based on an average trading volume of 5,500 shares, the days-to-cover ratio is presently 0.9 days. Approximately0.0% of the shares of the company are short sold.

Pharming Group Stock Performance

Shares of Pharming Group stock traded up $0.74 during trading on Monday, hitting $12.39. 15,715 shares of the company's stock were exchanged, compared to its average volume of 10,797. The stock has a market capitalization of $848.84 million, a price-to-earnings ratio of -95.31 and a beta of 0.02. The business has a 50-day simple moving average of $10.89 and a 200-day simple moving average of $9.68. Pharming Group has a 52-week low of $6.73 and a 52-week high of $17.08. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.07 and a current ratio of 2.79.

Pharming Group (NASDAQ:PHAR - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.06 earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.16. The business had revenue of $93.20 million during the quarter, compared to analyst estimates of $70.36 million. Pharming Group had a negative return on equity of 3.31% and a negative net margin of 2.19%. On average, research analysts forecast that Pharming Group will post -0.2 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its position in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) by 8.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,147 shares of the company's stock after purchasing an additional 4,150 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.08% of Pharming Group worth $557,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 0.03% of the company's stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.